Position in GUTS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$8,002
+$3,386 QoQ
Shares Held
10,080
+0.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#64
of 76 holders
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bank of New York Mellon Corp holds $4,845,290,998 across 311 Biotechnology names. GUTS ranks #307 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,672,623 | $830,842,010 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
758,492 | $472,950,091 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,578,013 | $380,253,782 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
492,071 | $148,128,128 | |
| 5 | INSM |
INSMED Inc
|
1,312,756 | $139,966,036 | |
| 6 | MRNA |
Moderna, Inc.
|
1,701,675 | $119,168,293 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
601,056 | $112,565,759 | |
| 8 | INCY |
Incyte Corp
|
972,825 | $110,279,435 |
All Filings in GUTS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,002 | 10,080 | Shares | Defined | 2026-08-06 | |
| 2026-03-31 | $4,616 | 10,079 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $22,173 | 10,079 | Shares | Defined | 2026-02-10 | |
| 2025-03-31 | $76,183 | 64,020 | Shares | Defined | 2025-04-29 | |
| 2024-12-31 | $85,382 | 41,448 | Shares | Defined | 2025-02-04 | |
| 2024-09-30 | $82,381 | 32,562 | Shares | Defined | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||